Results 21 to 30 of about 88,666 (249)

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [PDF]

open access: yes, 2001
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22.
Bench, AJ   +11 more
core   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

open access: yes, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
A Foudi   +56 more
core   +4 more sources

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

open access: yes, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T.   +18 more
core   +1 more source

Immunotherapy for acute myelogenous leukemia [PDF]

open access: yesBritish Journal of Cancer, 1973
One hundred and seven untreated patients with acute myelogenous leukaemia (AML) were admitted to St Bartholomew's Hospital between 10 October 1970 and 31 January 1973. Before receiving drugs to induce remission they were allocated alternatively into 2 groups to decide their remission treatment-a group to receive chemotherapy alone and a group to ...
R L, Powles   +11 more
openaire   +6 more sources

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

open access: yesHaematologica, 2015
The prognosis of older patients with acute myelogenous leukemia is generally poor. The interleukin-3 receptor α-chain (CD123) is highly expressed on the surface of acute leukemia cells compared with normal hematopoietic stem cells.
Erwin M. Lee   +12 more
doaj   +1 more source

A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]

open access: yes, 2015
Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela   +4 more
core   +3 more sources

Apoptotic effect of Bulbine Natalensis and Chlorophytum Comosum in myelogenous Leukemia K562 cell line

open access: yesBrazilian Journal of Biology, 2021
Bulbine natalensis and Chorophytum comosum are potential medicinal source for the treatment of cancers. Chronic myeloid leukaemia is a hematopoietic stem cells disorder treated by tyrosine kinase inhibitors but often cause recurrence of the leukaemia ...
B. Padayachee, F. Odun-Ayo, L. Reddy
doaj   +1 more source

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

open access: yes, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves   +37 more
core   +1 more source

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy

open access: yesCase Reports in Cardiology, 2018
Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes, chronic myelogenous leukemia, and acute myelogenous leukemia.
Pradyumna Agasthi   +4 more
doaj   +1 more source

Chronic myelogenous leukemia in Libya

open access: yesSouth Asian Journal of Cancer, 2012
Itrat Mehdi, Arshad Hussain Kashmiri
doaj   +4 more sources

Home - About - Disclaimer - Privacy